June 8 (Reuters) - Eli Lilly (LLY.N), opens new tab shares rose 4% on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results